Switching From Semaglutide to Tirzepatide: What to Know

Yes, you can switch from personalized compounded semaglutide to personalized compounded tirzepatide when your provider decides it fits. There is no do-it-yourself dose conversion: your provider decides when to stop one medicine, where the new one starts and how fast it rises. At Padgett in Ocala, personalized compounded tirzepatide starts at $229 a month.

Both are weekly injections, medically supervised at Padgett, with a dose personalized and adjusted with your provider over time. Personalized compounded tirzepatide in Ocala and personalized compounded semaglutide in Ocala each have their own page, and personalized compounded semaglutide and tirzepatide, compared sets them side by side.

Why do people think about switching?

People tend to ask when weight loss has slowed or stalled, when side effects wear on them, or when they want a medicine that works on two hormone pathways instead of one. The FDA-approved semaglutide label says semaglutide acts on the receptor for GLP-1, a natural hormone that helps regulate appetite. The FDA-approved tirzepatide label says tirzepatide acts on that receptor and on the one for GIP, a second hormone that lab and animal research suggests may further help regulate food intake.

In SURMOUNT-5, a 72-week head-to-head study of 751 adults with obesity but without type 2 diabetes, people randomly assigned to FDA-approved tirzepatide lost an average of 20.2% of their body weight, versus 13.7% with FDA-approved semaglutide. Each person took the highest dose they could tolerate.

SURMOUNT-5 assigned each person one medicine from the start; it did not test switching. The results are averages for FDA-approved products, not results for Padgett's personalized compounded medications, and yours may differ. If your loss has slowed, what a weight loss plateau on a GLP-1 means covers what to check with your provider first.

Side effects are another reason people ask, but a switch is not a sure cure: in SURMOUNT-5, digestive side effects were the most common in both groups, mostly mild to moderate and mainly while doses were being raised. Cost matters too, since personalized compounded tirzepatide starts at a higher monthly price. Thinking of quitting instead? See what happens when you stop a GLP-1 medication first.

Is there a dose conversion chart for switching?

No, and an online chart can't stand in for your provider. Neither FDA-approved label offers a conversion between the two. The semaglutide label's only switching directions cover moving between its own weekly injection and its daily tablet. The tirzepatide label sets one starting dose for all of its uses and gives no separate directions for people coming from another GLP-1 medicine.

A 2026 review of research on the FDA-approved products, published in Expert Opinion on Pharmacotherapy, says there are no guidelines for switching from semaglutide to tirzepatide, because the two work differently and are handled differently by the body. Its authors suggest rough dose ranges to guide prescribers and say exact conversions still have to be confirmed in switching studies.

Your own instructions, including how much you inject, are written for your exact personalized compounded medication, so the amount you used on one medicine doesn't carry over to the other. How personalized compounded tirzepatide doses work explains the steps once you start.

What does your provider weigh before you switch?

Your history on your current medicine, your health and every other medicine you take. Expect questions about how long you've been on personalized compounded semaglutide, the dose you reached, how your weight has changed, which side effects you've had and when you took your last injection.

Timing matters because both ingredients are long-acting. The FDA-approved semaglutide label puts its half-life, the time your body takes to clear half of it, at about 1 week, and says it stays in the bloodstream for about 5 to 7 weeks after a last dose at full maintenance strength. Both labels advise against using either one with another GLP-1 medicine, so never overlap the two or alternate between them on your own.

Where you start is a judgment call. The FDA-approved tirzepatide label's low starting dose and slow steps are there to lower the risk of digestive side effects. The 2026 review argues that always restarting at the lowest dose can leave a gap in treatment and risk weight regain. Your provider weighs both and decides.

Both FDA-approved labels carry a boxed warning about thyroid C-cell tumors and rule out anyone with a personal or family history of medullary thyroid cancer or with MEN 2 (multiple endocrine neoplasia syndrome type 2), so switching doesn't get around either one. Also mention pancreas, stomach, gallbladder, kidney or diabetic eye problems, any upcoming surgery, and any insulin or sulfonylurea, a type of diabetes pill, which the FDA-approved tirzepatide label says makes low blood sugar more likely.

Does switching affect birth control pills?

It can. The FDA-approved tirzepatide label says the medicine may make birth control pills less effective, because it slows stomach emptying, an effect that is strongest after the first dose and fades over time. It advises people on the pill to switch to a non-oral method, or add a barrier method such as condoms, for 4 weeks after starting and for 4 weeks after each dose increase. Hormonal birth control that you don't take by mouth should not be affected, the label says.

The label makes no exception for people who have already been on another GLP-1 medicine, and the window opens again with each increase, so tell your provider which method you use. Planning a pregnancy? Say so: the FDA-approved semaglutide label advises stopping it at least 2 months before a planned pregnancy because it lasts so long in the body.

What side effects should you expect after switching?

Digestive side effects are common when you start a new GLP-1 medicine, and they can show up even if your current one has gone smoothly. In the pooled weight-loss studies in the FDA-approved tirzepatide label, nausea affected 25% to 29% of people on the medicine, depending on the dose, against 8% on placebo, a shot with no medicine in it. Diarrhea affected 19% to 23% (8% on placebo), constipation 11% to 17% (5%) and vomiting 8% to 13% (2%).

Most nausea, vomiting and diarrhea in those studies happened while the dose was being raised, then eased. Switching does not rule that stage out: in a 12-week study of adults with type 2 diabetes who moved from a steady dose of another FDA-approved GLP-1 medicine directly to FDA-approved tirzepatide, 13.2% still had digestive side effects and 2% stopped the medicine because of side effects.

Drink fluids: the label warns that nausea, vomiting or diarrhea can dehydrate you, which may lead to kidney problems. Call your provider right away if nausea, vomiting or diarrhea is severe or won't stop, or if you have severe stomach pain that won't go away, sometimes reaching your back, a possible sign of an inflamed pancreas. The same goes for gallbladder signs: upper stomach pain, fever, yellow skin or eyes, or clay-colored stools.

Your provider may prescribe your weekly amount as two smaller injections, for example Monday and Thursday, when side effects call for it. Never change your schedule yourself. Splitting a tirzepatide dose twice a week explains how that works and what the FDA-approved label says; managing GLP-1 side effects has practical tips.

How does the cost change when you switch?

Your monthly price follows the medicine and dose you're prescribed. At Padgett, pricing is by dose: personalized compounded semaglutide starts at $149 a month and personalized compounded tirzepatide at $229 a month, both at the starting dose. The personalized compounded tirzepatide price list shows each of the other doses, and your cost can change whenever your dose does.

The monthly price is your medication. Your provider visit is $100 and is free when you start medication at that visit; the only other charge is a $50 no-show fee. Padgett is self-pay and has no contracts; paying for personalized compounded semaglutide without insurance explains how that works in Ocala.

How does switching work at Padgett in Ocala?

Your provider makes the decision with you. Visits are with Sarah Weir, APRN, an advanced practice registered nurse, at the clinic at 200 SW 8th St., Suite A, just south of downtown Ocala, or by telehealth from anywhere in Florida while you are physically in the state. Nothing is promised in advance; she decides with you.

Already on personalized compounded semaglutide at Padgett? Ask your provider or call the clinic, and keep following your current instructions until you get new ones. Coming from another clinic? Bring the name and dose of your current GLP-1 medicine, your last injection date, your side effects and a list of your other medicines and supplements, and fill out the intake forms texted from (352) 706-8733.

If you switch, your care stays medically supervised and the medication is shipped to your door in Florida. You book online, and nothing is charged when you book; a card on file holds your visit, and without one, the appointment isn't confirmed until staff reach you by phone. Questions first? Ask for the free consultation, a free 15-minute phone call with the medical staff; it is not a visit with the provider and nothing is prescribed on it.

When you're ready, book a weight-loss visit or call (352) 369-0104, Monday to Friday, 9:00 AM to 5:00 PM.

Personalized compounded semaglutide and personalized compounded tirzepatide are compounded drugs that have not been approved by the FDA. They have not been reviewed by the FDA for safety, effectiveness, or quality. FDA-approved products containing semaglutide and tirzepatide are available. Individual results vary.

This article is educational and is not medical advice. Talk with a licensed provider about your own health, medications and treatment options.